From: The role of the clinical research coordinator – data manager – in oncology clinical trials
Parameter | N | Median | Range |
---|---|---|---|
No. of current CTs* | 37 | 12.5 | 2.0–46.0 |
No. of multinational CTs | 33 | 4.0 | 0.0–17.5 |
No. of CTs by sponsorship: | 34 | ||
Pharmaceutical Industry | 4.0 | 0.0–30.0 | |
Cooperative Groups | 8.0 | 0.0–22.0 | |
No. of CTs by Phase: | 30 | ||
Phase I | 0.0 | 0.0–3.0 | |
Phase II | 5.0 | 0.0–14.0 | |
Phase III | 5.0 | 0.0–28.0 | |
Phase IV | 0.5 | 0.0–5.0 | |
Compassionate | 0.0 | 0.0–3.0 | |
No. of CTs by Indication: | 27 | ||
Breast cancer | 3.0 | 0.0–21.0 | |
Lung cancer | 3.0 | 0.0–13.0 | |
Colorectal cancer | 2.0 | 0.0–9.0 | |
Head & Neck cancer | 0.0 | 0.0–4.0 | |
Ovarian cancer | 0.0 | 0.0–2.0 | |
Other | 0.0 | 0.0–8.0 | |
No. of patients: | 33 | % | |
0–25 | NA | 30.3 | |
26–50 | NA | 15.2 | |
51–75 | NA | 6.1 | |
76–100 | NA | 12.1 | |
>100 | NA | 36.3 | |
No. of monitoring visits received: per month | 2.0 | 0.0–10.0 |